© 2017 The IBD Clinical and Research Centre

Created with wix.com

Crohn’s Disease Studies:

Higher vs Standard loading dose of Humira in moderate to severe Crohn’s disease

  • Naïve to Humira/Remicade (or stopped Remicade for reasons other than failure)

  • Cannot have tried Simponi, Stelara or Entyvio

  • Can be on stable dose of prednisone (< 40mg per day)

  • Can be on stable dose of immunosuppressant

 

**Receive standard loading dose OR higher loading dose of Humira.

 

THERE IS NO PLACEBO

 

Etrolizumab in moderate to severe Crohn's disease-Etrolizumab acts by specifically binding the integrin β7 subunit, found in both α4β7 which regulates trafficking and retention of leukocyte/lymphocyte subsets, respectively, in the intestinalmucosa.

  • Can have failed or been intolerant to steroids or immunosuppressives & anti-TNF

  • Can have non-draining fistulas

  • No prior use of Entyvio

 

**Currently on Cohort 2 so patients will receive either low dose or high dose Etrolizumab

 

THERE IS NO PLACEBO

Denosumab in Crohn's disease

  • Patients will undergo genetic test to see if they carry mutation in RANKL gene (75% with Crohn’s disease will have this mutation)

  • Patients will have evidence of ileocolonic, colonic, or ileal disease that is visualized either endoscopically on MRI within the past 6 months.

  • Receive 1 dose of active Denosumab.

 

THERE IS NO PLACEBO

 

STATIC in Crohn's Disease. You are invited to take part in a research study being conducted to help us understand the role of aminosalicylates in the treatment of Crohn’s Disease.

  • 18 years or older

  • Have a current, documented, diagnosis of Crohn’s disease, for at least 6 months and,

  • Be currently taking an aminosalicylate, for the last 6 months

Ulcerative Colitis Studies:

Higher vs Standard loading dose of Humira in moderate to severe Ulcerative Colitis

  • Previous benefit from Remicade however stopped for other reasons (i.e. personal choice or became pregnant)

  • Can be on stable dose of prednisone (< 40mg per day)

  • Can be on stable dose of immunosuppressant

  • May be included if they have previously experienced a benefit for their UC from infliximab and discontinued its use due to a subsequent loss of response or intolerance.

**Receive standard loading dose OR higher loading dose of Humira

THERE IS NO PLACEBO

 

APD334 in moderate to severe Ulcerative Colitis (Arena Pharma) *oral Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator (related to Etrasimod used n MS), prevents lymphocyte trafficking

  • Inadequate response, loss of response or Intolerance within the last 5 years , CS Therapy, 5-ASA, immunosuppressive therapy, Anti—TNF, therapy or Vedolizumab

  • Cannot have previous treatment with more than 3 biologic agents

 

Starting in October 2017:

Etrolizumab in moderate to severe UC- (Subcutaneous injection) - Etrolizumab acts by specifically binding the integrin β7 subunit, found in both α4β7 which regulates trafficking and retention of leukocyte/lymphocyte subsets, respectively, in the intestinal mucosa.

  • Can have failed or been intolerant to steroids or immunosuppressives & anti-TNF OR lost response

  • No prior use of Entyvio or other anti-integrin agents

  • Must have wash out of prior anti-TNF therapy of 8 weeks prior to randomization.

  • Can be on stable doses of Prednisone 30 mg/day, budesonide MMX, AZA, 6 MP, or MTX

 

 

For more information regarding our current clinical treatment trials please contact our Study Coordinators:

Melony Ivekovic @ 204-787-2060 or Diane McAlpine @ 204-787-1643